195 related articles for article (PubMed ID: 1958474)
1. In vivo administration of granulocyte-macrophage colony stimulating factor enhances neutrophil function in patients with myelodysplastic syndromes.
Verhoef G; Boogaerts M
Br J Haematol; 1991 Oct; 79(2):177-84. PubMed ID: 1958474
[TBL] [Abstract][Full Text] [Related]
2. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
Estey EH; Kurzrock R; Talpaz M; McCredie KB; O'Brien S; Kantarjian HM; Keating MJ; Deisseroth AB; Gutterman JU
Br J Haematol; 1991 Mar; 77(3):291-5. PubMed ID: 2012752
[TBL] [Abstract][Full Text] [Related]
3. Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on respiratory burst activity of neutrophils in patients with myelodysplastic syndromes.
Ohsaka A; Kitagawa S; Yuo A; Motoyoshi K; Furusawa S; Miura Y; Takaku F; Saito M
Clin Exp Immunol; 1993 Feb; 91(2):308-13. PubMed ID: 7679062
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
Shikama Y; Shichishima T; Ohto H; Jubinsky PT; Maruyama Y
Br J Haematol; 2000 Dec; 111(3):863-72. PubMed ID: 11122148
[TBL] [Abstract][Full Text] [Related]
5. Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF.
Zwierzina H; Herold M; Schöllenberger S; Geissler D; Schmalzl F
Br J Haematol; 1991 Nov; 79(3):438-43. PubMed ID: 1751371
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
Thompson JA; Lee DJ; Kidd P; Rubin E; Kaufmann J; Bonnem EM; Fefer A
J Clin Oncol; 1989 May; 7(5):629-37. PubMed ID: 2651578
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study.
Höffken K; Overkamp F; Stirbu J; Grothey A; Flasshove M; Hoelzer D; Ganser A
Onkologie; 1990 Feb; 13(1):33-7. PubMed ID: 2186322
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
[TBL] [Abstract][Full Text] [Related]
9. Modulation of neutrophil and monocyte function by recombinant human granulocyte macrophage colony-stimulating factor in patients with lymphoma.
Kharazmi A; Nielsen H; Hovgaard D; Borregaard N; Nissen NI
Eur J Clin Invest; 1991 Apr; 21(2):219-24. PubMed ID: 1905635
[TBL] [Abstract][Full Text] [Related]
10. Treatment of myelodysplastic syndromes with human granulocytic-macrophage colony stimulating factor (GM-CSF) or GM-CSF combined with low-dose cytosine arabinoside.
Economopoulos T; Papageorgiou E; Stathakis N; Asprou N; Karmas P; Dervenoulas J; Bouronikou H; Chalevelakis G; Raptis S
Eur J Haematol; 1992 Sep; 49(3):138-42. PubMed ID: 1446728
[TBL] [Abstract][Full Text] [Related]
11. Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients.
Kurzrock R; Talpaz M; Gomez JA; Estey EH; O'Brien S; Hirsch-Ginsberg C; Koller C; Freireich EJ; Gutterman JU
Br J Haematol; 1991 Jul; 78(3):352-8. PubMed ID: 1873220
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes.
Hansen PB; Johnsen HE; Hippe E; Hellström-Lindberg E; Ralfkiaer E
Am J Hematol; 1993 Dec; 44(4):229-36. PubMed ID: 8237992
[TBL] [Abstract][Full Text] [Related]
15. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3.
Maurer AB; Ganser A; Buhl R; Seipelt G; Ottmann OG; Mentzel U; Geissler RG; Hoelzer D
Leukemia; 1993 Nov; 7(11):1728-33. PubMed ID: 8231242
[TBL] [Abstract][Full Text] [Related]
16. Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor. (GM-CSF).
Economopoulos T; Papageorgiou E; Stathakis N; Constantinidou M; Parharidou A; Kostourou A; Dervenoulas J; Raptis S
Leuk Res; 1996 May; 20(5):385-90. PubMed ID: 8683977
[TBL] [Abstract][Full Text] [Related]
17. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.
Negrin RS; Haeuber DH; Nagler A; Olds LC; Donlon T; Souza LM; Greenberg PL
Ann Intern Med; 1989 Jun; 110(12):976-84. PubMed ID: 2471429
[TBL] [Abstract][Full Text] [Related]
18. Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; de Witte T; Jacobs A; Visiani G; Fiere D; Sonneveld P; Labar B
Infection; 1992; 20 Suppl 2():S116-23. PubMed ID: 1493935
[TBL] [Abstract][Full Text] [Related]
19. Combination of GM-CSF and cytosine in myelodysplasia results in improved neutrophil function.
Galvani DW; Dang Y; Watson F; Pumford D; Galazka A; Weiner J; Davies JM; Cawley JC
Acta Haematol; 1992; 87(3):129-35. PubMed ID: 1353646
[TBL] [Abstract][Full Text] [Related]
20. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
Thompson JA; Gilliland DG; Prchal JT; Bennett JM; Larholt K; Nelson RA; Rose EH; Dugan MH
Blood; 2000 Feb; 95(4):1175-9. PubMed ID: 10666187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
